Vnitřní lékařství 2/2020

P Ř EHLEDOVÉ Č LÁNKY Adipocytokíny a tyreopatie 18 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2020; 66(E-2): 13–18 / www.casopisvnitrnilekarstvi.cz 78. Stančík M, Mokáň M, Sádová I, et al. Úloha vaspínu v patogenéze koronárnej choroby srdca. Vnitř Lék 2015; 61: (Suppl. 2): 14–19. 79. Gonzalez CR, Caminos JE, Vazquez MJ, et al. Regulation of visceral adipose tissue-deri- ved serine protease inhibitor by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. Journal of Physiology. 2009; 587: 3741–3750. 80. Handisurya A, Riedl M, Vila G, et al. Serum vaspin concentrations in relation to insu- lin sensitivity following RYGB-induced weight loss. Obesity Surgery 2010; 20: 198–203. 81. Cinar N, Gülçelik NE, Aydín K, et al. Serum vaspin levels in hypothyroid patients. Eur J Endocrinol. 2011; 165: 563–569. 82. Samal B, Sun Y, Stearns G, et al. Cloning and characterization of the cDNA enco- ding a novel human pre-B-cell colony-enhancing factor. Mol and Cell Biol 1994; 14: 1431–1437. 83. Moschen AR, Kaser A, Enrich B, et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748–1758. 84. Tanaka M, Nozaki M, Fukuhara A, et al. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun 2007; 359: 194–201. 85. Chu CH, Lee JK, Wang MC, et al. Change of visfatin, C-reactive protein concent- rations, and insulin sensitivity in patients with hyperthyroidism. Metabolism 2008; 57: 1380–1383. 86. Han J, Zhang TO, Xiao WH, et al. Up-regulation of visfatin expression in subjects with hyperthyroidism and hypothyroidism is partially relevant to a nonlinear regulation me- chanism between visfatin and tri-iodothyronine with various concentrations. Chin Med J 2012; 125: 874–881. 87. MacLaren R, Cui W, Cianflone K Visfatin expression is hormonally regulated by meta- bolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Me- tab 2007; 9: 490–497. 88. Ozkaya M, Sahin M, Cakal E, et al. Visfatin plasma concentrations in patients with hy- perthyroidism and hypothyroidism before and after control of thyroid function. J Endo- crinol Invest 2009; 32: 435–439. 89. Caixàs A, Tirado R, Vendrell J, et al. Plasma visfatin concentrations increase in both hyper and hypothyroid subjects after normalization of thyroid function and are not re- lated to insulin resistance, anthropometric or inflammatory parameters. Clin Endocrinol (Oxf) 2009; 71: 733–738. 90. Imrich R Metabolické dôsledky chronického zápalu. In: Úvod do imunológie a pato- genéza vybraných autoimunitných ochorení. Bratislava: Vydavateľstvo UK 2016, 33–34. 91. Smékal A, Václavík J, Stejskal D, et al. Je u mladých pacientů s infarktemmyokardu mož- né vyšetřovat expresi adipokinů v leukocytech periferní krve? In: XXXII. dny mladých in- ternistů. Vnitř Lék 2013; 59: 1P1–1P36.